EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Therapeutic Potential of Photoimmunotherapy as a Safe, Effective and Non‐Toxic Treatment Option for Superficial Triple Negative Breast Cancer

Fleury Augustin Nsole Biteghe, Neelakshi Mungra iD, Zaria Malindi, Nyangone Ekome Toung Chalomie, Ketum Ateh Stanislas, Sayeda Yasmin-Karim, G Mike Makrigiorgos, Fallon Ester Chipidza, Olusiji Alex Akinrinmade, Srinivas Sridhar, Stefan Barth, Wilfred Ngwa

Cancer Medicine · 2025

DOI: 10.1002/cam4.71255 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Medicine, 2025. Verfasst von Fleury Augustin Nsole Biteghe und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Chemical Biology, College of Science, Northeastern University, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Immunotherapy, Phototherapy, Immunoconjugates. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 369 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Northeastern University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple‐negative breast cancer (TNBC) is the most aggressive breast cancer subtype, lacking estrogen (ER), progesterone (PR), and human epidermal growth factor receptor (HER‐2) expression. It disproportionately affects women of African descent and has a poor clinical prognosis attributed to its acute heterogeneity, thereby causing elevated mortality rates. Due to the lack of well‐defined molecular targets in TNBC, treatment relies heavily on a trimodality approach (surgery, radiotherapy, and chemotherapy), despite growing evidence of adverse effects and disease relapses. Therefore, there is an urgency to identify targetable aberrations for more effective approaches capable of selectively detecting and killing targeted cells while sparing healthy tissues. The emergence of monoclonal antibodies (mAbs) targeting tumor‐associated antigens (TAAs), which can be used as a carrier to deliver highly cytotoxic drugs, raised hopes that antibody‐drug conjugates (ADCs) might solve the toxicity‐therapy challenge by shifting the balance more toward beneficial therapeutic efficacy. Despite their therapeutic benefits, their clinical translation is limited by key developmental barriers, including immune‐related adverse events. To address these limitations, a novel approach using antibody‐photoconjugates (APCs) was developed for photoimmunotherapy (PIT) applications, whereby local exposure to near‐infrared (NIR) light induces targeted phototoxic damage, culminating in apoptotic, necrotic, and immunogenic cell death (ICD) with minimal toxicities. Therefore, this review highlights the potential of PIT as an inherently safer and efficient light‐dependent therapeutic option for treating TNBC. Trial Registration: NCT06449222

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsImmunotherapyPhototherapyImmunoconjugatesHumansFemale

Stichwörter der Autor:innen

antibody drug conjugateantibody photoconjugateimmunogenic cell deathphotoimmunotherapytriple‐negative breast cancer

Substanzen

Immunoconjugates

Autor:innen und Institutionen

  • Department of Chemistry and Chemical Biology, College of Science, Northeastern University, Boston, Massachusetts, USA.
  • Centre for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, Washington, USA.
  • Faculty of Health Sciences, Laser Research Centre, University of Johannesburg, Johannesburg, South Africa.
  • Medical Biotechnology and Immunotherapy Research Unit, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
  • Biopharmaceutical Training Laboratory (BATL), College of Professional Studies, Northeastern University, Burlington, Massachusetts, USA.
  • Johns Hopkins School of Medicine, Baltimore, Maryland, USA.

ORCID-Profile: Neelakshi Mungra

Förderung

  • Northeastern University

Zitieren

APA

Biteghe, F. A. N., Mungra, N., Malindi, Z., Chalomie, N. E. T., Stanislas, K. A., Yasmin-Karim, S., Mike Makrigiorgos, G., Chipidza, F. E., Akinrinmade, O. A., Sridhar, S., Barth, S., & Ngwa, W. (2025). The Therapeutic Potential of Photoimmunotherapy as a Safe, Effective and Non‐Toxic Treatment Option for Superficial Triple Negative Breast Cancer. Cancer Medicine. https://doi.org/10.1002/cam4.71255

Vancouver

Biteghe FAN, Mungra N, Malindi Z, Chalomie NET, Stanislas KA, Yasmin-Karim S, et al. The Therapeutic Potential of Photoimmunotherapy as a Safe, Effective and Non‐Toxic Treatment Option for Superficial Triple Negative Breast Cancer. Cancer Medicine. 2025. doi:10.1002/cam4.71255

BibTeX
@article{Biteghe2025,
  author = {Biteghe, Fleury Augustin Nsole and Mungra, Neelakshi and Malindi, Zaria and Chalomie, Nyangone Ekome Toung and Stanislas, Ketum Ateh and Yasmin-Karim, Sayeda and Mike Makrigiorgos, G and Chipidza, Fallon Ester and Akinrinmade, Olusiji Alex and Sridhar, Srinivas and Barth, Stefan and Ngwa, Wilfred},
  title = {The Therapeutic Potential of Photoimmunotherapy as a Safe, Effective and Non‐Toxic Treatment Option for Superficial Triple Negative Breast Cancer},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.71255}
}
Kostenlos starten →